Clinical Trial Update: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of a four-drug regimen (polatuzumab vedotin, venetoclax, rituximab, and hyaluronidase) in relapsed or refractory mantle cell lymphoma; the trial w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Hyaluronidase, human (hyaluronidase (human))
• Rituximab (rituximab)
• Venetoclax (venetoclax)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19